BioMarin to Buy Amicus in $4.8 Billion Bet on Rare Diseases (2)

BioMarin Pharmaceutical Inc. agreed to buy Amicus Therapeutics Inc. for about $4.8 billion, helping the biotech company expand its portfolio of treatments for rare diseases.

Amicus shareholders will receive $14.50 a share in cash, a 33% premium to the last closing price. The deal is expected to close in the second quarter of 2026 subject to shareholder and regulatory approval, the companies said in a statement Friday.

Amicus jumped 31% at 9:46 a.m. in New York, its biggest gain in more than a decade. The biotech firm’s shares had already risen nearly 16% year to date through Thursday’s close. BioMarin ...